VLP Therapeutics Funding: $37M Raised, Series A (2023)

VLP Therapeutics funding overview

VLP Therapeutics is based in Gaithersburg. VLP Therapeutics has raised $37M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in December 2023. The round record for VLP Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Sojitz Corporation, Nobelpharma Co., Ltd., MUFG Bank, Ltd., MIYAKO Capital Co., Ltd., Robert G. Hisaoka, SK Impact Fund, LLC. 6 distinct backers are named across the disclosed rounds.

VLP Therapeutics at a glance

Total raised: $37M
Latest round: Series A
Latest round date: December 2023
Headquarters: Gaithersburg
Notable investors: Sojitz Corporation, Nobelpharma Co., Ltd., MUFG Bank, Ltd., MIYAKO Capital Co., Ltd., Robert G. Hisaoka, SK Impact Fund, LLC

Frequently asked about VLP Therapeutics funding

How much has VLP Therapeutics raised?: VLP Therapeutics has raised $37M in total disclosed funding across the rounds on record.
Who has invested in VLP Therapeutics?: Sojitz Corporation, Nobelpharma Co., Ltd., MUFG Bank, Ltd., MIYAKO Capital Co., Ltd., Robert G. Hisaoka, SK Impact Fund, LLC are named among the investors backing VLP Therapeutics.
What was the latest VLP Therapeutics funding round?: The most recent disclosed round is a Series A, announced in December 2023.
Where is VLP Therapeutics based?: VLP Therapeutics is based in Gaithersburg.
When did VLP Therapeutics last raise?: The last disclosed VLP Therapeutics round closed in December 2023 at Series A.

Totals shown for VLP Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Gaithersburg and the investors behind them below.

VLP Therapeutics Funding: $37M Raised, Series A (2023)

VLP Therapeutics funding overview

VLP Therapeutics at a glance

Frequently asked about VLP Therapeutics funding

Companies related to VLP Therapeutics (38)

Browse related funding lists (3)